Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Completed · Phase 3
Conditions studied: Iron Deficiency Anaemia, Iron Deficiency Anemia
In brief
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
Key facts
- Study ID
- NCT03238911
- Run by
- Pharmacosmos A/S
- People needed
- 123
- Starts
- 2017-10-24
- Expected to finish
- 2018-06-19
- Last updated by the study team
- 2020-02-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pharmacosmos Investigational Site — Los Angeles, California, United States
- Pharmacosmos Investigational Site — Sacramento, California, United States
- Pharmacosmos Investigational Site — Santa Ana, California, United States
- Pharmacosmos Investigational Site — Clearwater, Florida, United States
- Pharmacosmos Investigational Site — Miami, Florida, United States
- Pharmacosmos Investigational Site 1 — Miami, Florida, United States
- Pharmacosmos Investigational Site 2 — Miami, Florida, United States
- Pharmacosmos Investigational Site — Miami, Florida, United States
- Pharmacosmos Investigational Site — Miami, Florida, United States
- Pharmacosmos Investigational Site — Indianapolis, Indiana, United States
- Pharmacosmos Investigational Site — Wichita, Kansas, United States
- Pharmacosmos Investigational Site — Metairie, Louisiana, United States
- Pharmacosmos Investigational Site — Lancaster, Pennsylvania, United States
- Pharmacosmos Investigational Site — Houston, Texas, United States
- Pharmacosmos Investigational Site — Orem, Utah, United States
- Pharmacosmos Investigational Site — Leesburg, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.